INVEGA SUSTENNA® Safety Profile: Lipids

Cholesterol

From 4 placebo-controlled, 9- to 13-week, fixed-dose studies1

lipids cholesterol

LDL

From 4 placebo-controlled, 9- to 13-week, fixed-dose studies

lipids ldl

HDL

From 4 placebo-controlled, 9- to 13-week, fixed-dose studies

lipids hdl

Triglycerides

From 4 placebo-controlled, 9- to 13-week, fixed-dose studies

lipids triglycerides

DYSLIPIDEMIA: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.1

Please see Important Safety Information.

*Initial deltoid injection of 234-mg followed by 39-mg, 156-mg, or 234-mg every 4 weeks by deltoid or gluteal injection. Other dose groups (39-mg, 78-mg, and 156-mg) are from studies involving only gluteal injection.

Study Design

Results from 4 placebo-controlled (one 9-week and three 13-week), fixed-dose studies of adult patients experiencing an acute exacerbation of schizophrenia.1

Reference: 1. INVEGA SUSTENNA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; January 2019.